论文部分内容阅读
目的 了解肾移植患者体内普乐可复 (FK5 0 6 )药代动力学特征 ,为临床制定个体化用药方案提供依据 .方法 采用微粒子酶免分析仪测定用药前后不同时间全血中 FK5 0 6浓度 ,以 3P97药动学程序拟合求算 FK5 0 6药动学参数 .结果 在患者 po FK5 0 6 (9m g/ 12 h)达稳定态后 FK5 0 6在体内处置为一室开放模型 ,药动力学参数 Tmax,ρmax,T1 /2 ke,AUC分别为 1.2 h,75 .3mg· L- 1 ,3.9h和 5 2 6 .6 mg· h· L- 1 ,全血浓度波动差值为 6 3.4mg· L- 1 .结论 为降低 FK5 0 6全血浓度波动范围 ,采用 8h一次 po FK5 0 6更为适宜 ,同时应加强 FK5 0 6血药浓度监测 ,确保用药安全和有效
Objective To understand the pharmacokinetics of leptokadrate (FK506) in renal transplant recipients and to provide a basis for the development of individualized drug regimens in clinical practice.Methods The concentration of FK506 in whole blood at different time points , And the pharmacokinetic parameters of FK506 were calculated by 3P97 pharmacokinetic program.Results FK5 0 6 was treated as a one-compartment open model in vivo after poFK5 0 6 (9 m g / 12 h) reached the steady state The kinetic parameters Tmax, ρmax, T1 / 2 ke and AUC were 1.2 h, 75.3 mg · L-1, 3.9 h and 526.6 mg · h · L-1 respectively. The difference of the whole blood concentration was 6 3.4mg · L- 1. Conclusions In order to reduce the fluctuation range of FK506 whole blood concentration, it is more appropriate to use poFK5 0 8h once, and strengthen the monitoring of FK506 blood serum concentration to ensure safe and effective medication